azacitidine and plx4032

azacitidine has been researched along with plx4032 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ	1
Bollag, G; Bornman, WG; Davies, MA; Dayyani, F; Desai, J; Gallick, GE; Gopal, YN; Jiang, ZQ; Kopetz, S; Lemos, R; Mao, M; Mariadason, JM; Mills, GB; Powis, G; Tang, XM; Tian, F; Tsao, CC; Wistuba, II	1

Other Studies

2 other study(ies) available for azacitidine and plx4032

Article	Year
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15 Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship	2013
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Feb-01, Volume: 19, Issue:3 Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Indoles; Methylation; Mice; Mitogen-Activated Protein Kinases; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sulfonamides; Vemurafenib	2013

Article

Year

Identification of potent Yes1 kinase inhibitors using a library screening approach.

Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Feb-01, Volume: 19, Issue:3

Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Indoles; Methylation; Mice; Mitogen-Activated Protein Kinases; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sulfonamides; Vemurafenib

2013